| 09:00 - 10:00 |
Morning Plenary Session |
Plenary Hall |
| 09:00 - 09:15 | Chairperson: Prof. Michael Sela
Weizmann Institute, Israel
Prof. Rami Rahamimov
Chief Scientist, Ministry of Health
Welcome from the Ministry of Health |
|
| 09:15 - 10:00 |
Keynote Speaker: Prof. Leroy Hood
Institute for Systems Biology, USA
Systems Biology: Transforming Biology And Medicine |
|
| 10:00 - 11:30 |
The Cancer Session |
Plenary Hall |
| 10:00 - 10:30 | Prof. Aaron Ciechanover
Technion, Israel
The Ubiquitin Proteolytic System - From a Vague Idea Through Basic Mechanisms and onto Human Diseases and Drug Targeting |
|
| 10:30 - 11:00 | Dr. Julian Adams
Infinity Pharmaceuticals, USA
The Proteasome as a Cancer Target: The Discovery and Development of Velcade |
|
| 11:00 - 11:30 | Prof. Michael Welch
Washington University School of Medicine, USA
Positron Emission Tomography-Applications in Medical Diagnosis and Drug Discovery |
|
| 11:30 - 12:00 |
COFFEE BREAK |
|
| 12:00 - 13:15 |
Cancer Session- Company Presentations-Parallel Sessions |
|
| |
| HALL A |
HALL B |
HALL C |
Session Chairperson:
Dr. G. Ehrlich |
Session Chairperson
Dr. O. Dar |
Session Chairperson
Mr D. Furst |
Y. Daniely
GAMIDA-CELL LTD
Stem Cell Expansion Technology: Expectations for 2005/2006 |
S. Larisch
SIMETRA PHARM LTD
The Pro Apoptotic IAP Antagonist "ARTS" Protein Mimetics as Anti Cancer Drugs
| Z. Bentwich
ROSETTA GENOMICS LTD
Discovery of Hundreds of Novel Disease-Related Human Microrna’s-Key Regulators of Protein Translation |
N. Hechter
SUPERDIMENSION LTD
Electromagnetic Navigation to Peripheral Lesions and Lymph Nodes in the Lungs |
M. Peled-Kamar
BIOMIMIC PHARMA LTD
Biomimic Pharma:T-Cell Receptor Like (TCRL) Antibodies for Cancer Therapy | Z. Agur
OPTIMATA LTD
Optimata’s Virtual Cancer Patient Engine for Accelerating the Translational Path in Drug Development |
N.J. Mabjeesh
TEL AVIV SOURASKY MEDICAL CENTER
The Mammalian Septin Msf-A Interactes With Hif-1; And Augments Hif-1 Transcriptional Activation |
A.L.Salzman
INOTEK PHARMACEUTICALS CORP
Parp Inhibitor Prophylaxis for Radical Nerve Sparing Prostatectomy Induced Erectile Dysfunction | C.S. Irving
THERAVIR MANAGEMENT L.P
PhaseI/II Trial of Intravenous Ndv-Huj Virotherapy in Recurrent Glioblastoma Multiforme |
M. Schickler
CURETECH LTD
Curetech-Harnessing the Immune System to Combat Cancer |
Y.Tikochinski
GENETICO LTD
Rna-Switch Technology for Drug Targeting |
A. Zangen, BRAINSWAY
Transcranial Magnetic Stimulation of Deep Brain Regions |
J.M. Van Gelder
INSIGHT BIOPHARMACEUTICALS LTD
Novel Small-Molecule Heparanase Inhibitors for the Treatment of Cancer |
A. Peled
BIOKINE THERAPEUTICS LTD
The Chemokine Receptor Cxcr4, A Novel Therapeutic Target for Cancer |
N. Shani
COMPUGEN
Cancer Biomarkers Discovery |
|
|
| 13:00 - 14:00 |
LUNCH BREAK |
|
| 14:00 - 16:15 | Afternoon Plenary Session-Biotechnology 2005
| Plenary Hall |
| |
Chairperson: Mr. Claudio Yarza
PricewaterhouseCoopers, Israel |
|
| 14:00 - 14:45 | Keynote Speaker: Mr Steven Burrill
CEO Burrill & Co
The Life Science Industry - A Global Perspective |
|
| 14:45 - 16:15 |
PANEL -The Life Science Industry - An Israeli Perspective |
|
| | Moderator: Prof Itzhak Ben Israel
Tel Aviv University
Panelists
Mr. Yossi Bachar
Ministry of Finance, Israel
Dr. Monica Darnbrough CBE
Dept of Trade & Industry, UK
Mr. Daniel Shemi
Royal Danish Embassy, Israel
Prof. Tony Weiss
University of Sydney, Australia
Dr. Shimon Eckhouse
Syneron, Israel
Mr. Israel Makov
Teva, Israel |
|
| |
CLOSING REMARKS BY DR AHARON SCHWARTZ-CONFERENCE CHAIRPERSON |
|
![BIO-TECH ISRAEL 2005: The Israel Biomedical Technologies CONFERENCE AND EXHIBITION [Tel Aviv, Israel, May 24-26, 2005]](images/bioLogo.gif)
![BIO-TECH ISRAEL 2005: The Israel Biomedical Technologies CONFERENCE AND EXHIBITION [Tel Aviv, Israel, May 24-26, 2005]](images/forTop.gif)
